Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors.

MLA

Dunn, Amy, et al. “Bleed Treatment with Eptacog Beta (RFVIIa) Results in a Low Incidence of Rebleeding in Adult and Adolescent Patients with Haemophilia A or B with Inhibitors.” Haemophilia, Dec. 2024, p. 1. EBSCOhost, https://doi.org/10.1111/hae.15109.

APA

Dunn, A., Dargaud, Y., Abajas, Y., Carcao, M., Castaman, G., Giermasz, A., Hermans, C., Jiménez, Y. V., Lewandowska, M., Mahlangu, J., Meeks, S., Miesbach, W., Recht, M., Salinas, V., Chrisentery, S. T., Bonzo, D., Mitchell, I. S., Wilkinson, T. A., & Young, G. (2024). Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors. Haemophilia, 1. https://doi.org/10.1111/hae.15109

Chicago

Dunn, Amy, Yesim Dargaud, Yasmina Abajas, Manuel Carcao, Giancarlo Castaman, Adam Giermasz, Cédric Hermans, et al. 2024. “Bleed Treatment with Eptacog Beta (RFVIIa) Results in a Low Incidence of Rebleeding in Adult and Adolescent Patients with Haemophilia A or B with Inhibitors.” Haemophilia, December, 1. doi:10.1111/hae.15109.